Sex Differences in Angiotensin II-Induced Hypertension in Mi
2026-06-02
Sex Differences in Angiotensin II-Induced Hypertension: Insights from Conscious Mouse Models
Study Background and Research Question
Hypertension is a leading risk factor for cardiovascular disease, and mounting evidence indicates significant sex-dependent variability in its incidence and progression. Epidemiological and preclinical data show that males often develop more severe hypertension than females, with sex hormones believed to mediate these differences. While prior work explored genetic and induced models in rats, the specific influence of sex on the development of angiotensin II (ANG II)-induced hypertension in conscious mice remained uncharacterized. The research by Xue, Pamidimukkala, and Hay (reference study) addresses this gap, asking: How do sex and gonadal hormones affect the trajectory and mechanisms of ANG II-driven hypertension in conscious mice?Key Innovation from the Reference Study
The principal innovation of this study lies in its direct, quantitative comparison of hypertensive responses between male and female conscious mice subjected to chronic ANG II infusion. The researchers not only established clear sex-based differences in blood pressure (BP) elevation but also dissected the roles of gonadal hormones and autonomic regulation using telemetry, baroreflex testing, and ganglionic blockade. This approach enabled a nuanced analysis of how α1-adrenergic receptor signaling and sympathetic activity intersect with hormonal status to drive cardiovascular outcomes.Methods and Experimental Design Insights
To capture physiologically relevant cardiovascular dynamics, the study utilized telemetry implants for continuous monitoring of aortic BP and heart rate (HR) in freely moving, conscious mice. Mice received systemic ANG II (800 ng·kg⁻¹·min⁻¹) via subcutaneous osmotic pumps. Both intact and gonadectomized male and female mice were included to isolate the contributions of sex hormones. Key experimental features included:- Baseline measurement of BP and HR in all groups before intervention.
- Chronic ANG II infusion for 7 days, with continuous hemodynamic recording.
- Pharmacological assessment of baroreflex sensitivity using phenylephrine-induced bradycardia.
- Ganglionic blockade to quantify sympathetic nerve activity’s contribution to BP maintenance post-ANG II.
Protocol Parameters
- ANG II dose: 800 ng·kg⁻¹·min⁻¹ administered via subcutaneous osmotic pump for 7 days.
- Telemetry monitoring: Implantation prior to intervention to measure aortic BP and HR continuously in conscious mice.
- Gonadectomy: Performed in separate cohorts to assess the influence of sex hormones on hypertensive response.
- Baroreflex assessment: Phenylephrine administered intravenously to evaluate reflex bradycardia before and during ANG II infusion.
- Sympathetic blockade: Ganglionic blockers used on day 7 post-ANG II to estimate sympathetic contribution to BP maintenance.
Core Findings and Why They Matter
The study found that baseline BP did not differ significantly between sexes. However, chronic ANG II infusion produced a substantially greater increase in BP in male mice (average 35.1 mmHg) compared to female mice (7.2 mmHg), as reported in the reference study. Gonadectomy modulated these responses: removal of testes reduced the hypertensive response in males (to 15.2 mmHg), while ovariectomy amplified it in females (to 23.1 mmHg). These results point to a protective effect of female sex hormones and a contributory role of male hormones in ANG II-driven hypertension. Importantly, the study also showed that ANG II infusion blunted the baroreflex bradycardia response to phenylephrine in males but not females, indicating a sex-specific resetting of baroreflex control. Ganglionic blockade revealed a greater sympathetic contribution to BP maintenance in males post-ANG II, suggesting enhanced adrenergic receptor mediated vasoconstriction in this group. These findings are significant because they:- Demonstrate that sex is a critical biological variable in hypertensive pathophysiology and experimental design.
- Implicate α1-adrenergic receptor signaling and sympathetic activity as mediators of sex-dependent BP regulation.
- Highlight the need to consider hormonal status when modeling hypertension and evaluating therapeutic interventions.
Comparison with Existing Internal Articles
Recent reviews, such as "L-Phenylephrine: Precision in α1A Adrenergic Signaling Research" and "L-Phenylephrine: A Precision Tool for α1A Receptor Signaling Research", have discussed the utility of selective adrenergic α1A receptor agonists in dissecting cardiovascular signaling pathways, including sex-dependent outcomes and baroreflex mechanisms. These resources emphasize the translational and protocol optimization potential of using tools such as L-Phenylephrine to model α1-adrenergic receptor signaling in vitro and in vivo, and support the approach taken in the reference study for evaluating autonomic and hormonal influences on BP regulation. The present study provides robust in vivo evidence that complements these articles by directly quantifying sex differences in a physiologically relevant hypertension model and linking these differences to baroreflex function and sympathetic output.Limitations and Transferability
While the study’s use of conscious, freely moving mice and direct telemetry strengthens its translational relevance, several limitations must be considered:- Findings in mice may not fully extrapolate to human hypertension due to interspecies differences in cardiovascular regulation and hormonal milieu.
- The study focused on systemic ANG II infusion; localized or pulsatile delivery might yield different outcomes.
- While baroreflex and sympathetic activity were assessed, downstream molecular mechanisms (e.g., IL-6 mRNA regulation or cardiac hypertrophy signaling) were not directly measured and would require additional studies.